Lars Lindholm
Impact in
- Cardiology and Cardiovascular Medicine top 0.05%
- Blood Pressure and Hypertension Studies
- Renin-Angiotensin System Studies
- Heart Rate Variability and Autonomic Control
- Cardiovascular Health and Disease Prevention
- Heart Failure Treatment and Management
- Endocrinology, Diabetes and Metabolism top 0.05%
- Hormonal Regulation and Hypertension
Papers in
-
- Blood Pressure and Hypertension Studies 118
- Heart Rate Variability and Autonomic Control 19
- Co-authors
- Ulf dé FairéSverre E. KjeldsenHans IbsenRichard B. DevereuxMarkku S. NieminenStevo JuliusBjörn DahlöfBengt Scherstén
- Journals
- Journal of Hypertension (36 papers)The Lancet (18 papers)Blood Pressure (16 papers)Health Policy (12 papers)BMC Public Health (12 papers)
- Partner nations
- SwedenUnited StatesDenmark
In The Last Decade
Lars Lindholm
332 papers receiving 19.3k citations
Hit Papers
Peers
Comparison fields: 5 of 194
- Cardiology and Cardiovascular Medicine 14.1k
- Endocrinology, Diabetes and Metabolism 6.5k
- Nephrology 1.3k
- Geriatrics and Gerontology 625
- Nutrition and Dietetics 2.2k
Countries citing papers authored by Lars Lindholm
This map shows the geographic impact of Lars Lindholm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Lindholm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Lindholm more than expected).
Fields of papers citing papers by Lars Lindholm
This network shows the impact of papers produced by Lars Lindholm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Lindholm. The network helps show where Lars Lindholm may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Lindholm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 2 | |
| 3 | 2020 | 23 | |
| 4 | 2020 | 2 | |
| 5 | 2019 | 26 | |
| 6 | 2019 | 8 | |
| 7 | 2018 | 23 | |
| 8 | 2018 | 20 | |
| 9 | 2016 | 16 | |
| 10 | 2016 | 3 | |
| 11 | Early invitation to prenatal food combined with multiple micronutrients is cost-effective compared to iron-folic acid supplementations : results from MINIMat trial | 2013 | 6 |
| 12 | Abstract 4421: Concomitant Hydrochlorothiazide Therapy in Hypertensive Patients is Associated with Reduced Cardiovascular Morbidity and Mortality Independent of Blood Pressure and Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study | 2008 | 2 |
| 13 | Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study | 2006 | 1 |
| 14 | High hemoglobin was associated with cardiovscular events, low hemoglobin with all-cause mortality, and large fall in hemoglobin with both in patients with hpertension and left ventricular hypertrophy. : The LIFE study | 2006 | 2 |
| 15 | Regression of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus hypertensive patients : The LIFE study | 2005 | 2 |
| 16 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. | 2003 | 2 |
| 17 | 2002 | 24 | |
| 18 | [Treatment of high blood pressure still unchanged. Diuretics and beta-blockaders are first choice preparations]. | 1998 | 1 |
| 19 | [The "green keyhole" project for public health. The effect of society's impact on health is difficult to measure]. | 1997 | 2 |
| 20 | Treating hypertension in the elderly. | 1993 | 1 |
About Lars Lindholm
Lars Lindholm is a scholar working on Cardiology and Cardiovascular Medicine, Geriatrics and Gerontology, Endocrinology, Diabetes and Metabolism, Family Practice and General Health Professions, having authored 343 papers that have together received 20.8k indexed citations. Recurring topics across this work include Blood Pressure and Hypertension Studies (118 papers), Health Systems, Economic Evaluations, Quality of Life (60 papers), Hormonal Regulation and Hypertension (42 papers), Global Health Care Issues (30 papers), Global Maternal and Child Health (27 papers), Healthcare Systems and Reforms (24 papers), Health disparities and outcomes (21 papers) and Heart Rate Variability and Autonomic Control (19 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (14.1k citations), Endocrinology, Diabetes and Metabolism (6.5k citations), Nephrology (1.3k citations), Geriatrics and Gerontology (625 citations) and Nutrition and Dietetics (2.2k citations). Lars Lindholm has collaborated with scholars based in Sweden, United States and Denmark. Frequent co-authors include Ulf dé Fairé, Sverre E. Kjeldsen, Hans Ibsen, Richard B. Devereux, Markku S. Nieminen, Stevo Julius, Björn Dahlöf, Bengt Scherstén, Bo Carlberg and Ola Samuelsson. Their work appears in journals such as Journal of Hypertension, The Lancet, Blood Pressure, Health Policy and BMC Public Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.